Physicians See New Benefits, Treatment Opportunities for Brain Cancer with Elekta's Leksell Gamma Knife Perfexion

Press releases may be edited for formatting or style | July 01, 2010

The University of Virginia (UVA) was the first U.S. center to acquire Extend. "We wanted to expand the versatility of Perfexion to allow multi-session radiosurgery," says Jason Sheehan, M.D., Ph.D., and co-director of UVA's Gamma Knife Center. "Extend enabled us to treat lesions immediately adjacent to critical structures, such as the optic apparatus, in addition to targets too large for single session radiosurgery. It also created the potential to treat brain metastases, which in many cases may not require the precision provided by a very rigid frame."

New GammaPlan® software reinforces the ability of the Perfexion system to provide an individualized treatment. In brain metastases cases, for example, clinicians can design a therapy that accounts for the patient's number, size and location of mets and fine-tune the dose for optimal tumor targeting and avoidance of normal tissues. Planning time has been reduced to enable plan development in less than an hour, while the median reduction in setup time has been reduced by 53 minutes per patient. (3)

We repair MRI Coils, RF amplifiers, Gradient Amplifiers and Injectors.

MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013

The advantages of Perfexion were widely reported at the Leksell Gamma Knife Society meeting in Athens, Greece. Interviews and results of some of the clinical findings are available online at www.elekta.com/cmd2010.
--
(1) American Cancer Society. Cancer Facts & Figures 2010. Atlanta: American Cancer Society; 2010.

(2) Chang, E. L. et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncology. 10, 1037-1044; 2009.

(3) Niranjan, et al. Efficiency and Dose Planning Comparison Between the Perfexion and 4C Leksell Gamma Knife Units. Stereotactic and Functional Neurosurgery. 87, 191-198; 2009.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.

Back to HCB News